Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial

• Status: Completed
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The proposed study is designed to evaluate the effect of an intravenous infusion of magnesium sulfate in facilitating successful cardioversion of atrial fibrillation and in decreasing the energy threshold (in J) required for successful cardioversion of atrial fibrillation into sinus rhythm.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: State University of New York at Buffalo
• Treatments: Magnesium Sulfate

Criteria

Inclusion Criteria:

• Patient with new onset Atrial fibrillation less than 48 hours after onset undergoing electrical cardioversion.

• Patients with atrial fibrillation longer than 48 hours on warfarin with documented therapeutic INR levels >2 for at least 3 weeks prior to the cardioversion, or been on dabigatran for 3 weeks, or a transesophageal echocardiogram on the day of the procedure that excludes intracardiac thrombi, undergoing electrical cardioversion.

Exclusion Criteria:

• Creatinine >2.0 mg/dl

• Potassium level less than 3.5 mmol/dl

• TSH < 0.5

• Magnesium levels >3.0 mg/dl

• Urgent need for cardioversion (e.g., hemodynamic instability, unstable angina, pulmonary edema)

• Patients with recent (less than 6 weeks) acute myocardial infarction

• Patients post-cardiac surgery

• Pregnant women

• Patients who are being treated with antiarrhythmic drugs who have received less than five doses of the drug. For amiodarone, patients who have received less than three weeks prior to cardioversion are excluded.